pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,299 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT800Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace70raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Tau in the spotlight at Alzheimer’s conference
    From STAT's AAIC in 30 newsletter: Researchers focus on tau, and progress on crossing the blood-brain barrier.
    STAT · 16d ago↗ source
  • Nominee for key federal health role has a history of questioning vaccines
    Sean Kaufman's views on vaccines may put him at odds with Sen. Bill Cassidy during next week's confirmation hearing.
    STAT · 18d ago↗ source
  • GSK, Hansoh ADC extends survival in lung cancer study
    GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
    BioPharma Dive · 18d ago↗ source
← prev
page 14 of 52
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Roche ends Huntington’s gene-silencing programs
    ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
    STAT · 18d ago↗ source
  • STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
    German lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the government
    STAT · 18d ago↗ source
  • ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
    BioPharma Dive · 18d ago↗ source
  • FDA quietly pushes back deadline on electric shock ban
    Massachusetts' biggest nursing strike ever, tackling the male loneliness epidemic, and other health news for Morning Rounds
    STAT · 18d ago↗ source
  • Opinion: The primary care crisis paradox
    “Solving the health crisis in the United States will require confronting things far harder than readjusting a fee schedule.”
    STAT · 18d ago↗ source
  • New York boys club has a time-tested recipe to protect members’ mental health
    At a time when attention is deservedly being turned to the mental health crisis in boys, the Boys' Club of New York is a shelter from the storm for many…
    STAT · 18d ago↗ source
  • STAT+: How a Boston doctor built a following as a ‘loud and unafraid’ voice in the Trump era
    Jeremy Faust saves lives in the ER and breaks stories with his Inside Medicine newsletter. He’s also testing the bounds of news reporting.
    STAT · 18d ago↗ source
  • Roche scraps two Ionis-partnered Huntington’s drugs
    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
    BioPharma Dive · 19d ago↗ source
  • Whistleblower takes on health insurance and FDA commissioner candidates
    This week on "The Readout LOUD" podcast: Why does getting family health insurance through a job cost as much as buying a new car? And who might be the new…
    STAT · 19d ago↗ source
  • GSK ends brain drug alliance with Alector
    Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
    BioPharma Dive · 19d ago↗ source
  • Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
    An outbreak of diarrhea-causing parasite has grown to more than 1,000 cases, making it one of the nation’s largest such outbreaks in years.
    STAT · 19d ago↗ source
  • STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
    An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.
    STAT · 19d ago↗ source
  • STAT+: FDA finalists under review
    Three top contenders to run the FDA are under review by the White House
    STAT · 19d ago↗ source
  • STAT+: Prime wins Beam arbitration, clearing path to clinic
    AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The Readout
    STAT · 19d ago↗ source
  • STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
    The White House is reviewing a list of three top contenders for the FDA commissioner post
    STAT · 19d ago↗ source
  • STAT+: OpenEvidence backs study that finds it beats LLMs
    In this edition of STAT Health Tech: Dueling research pitting OpenEvidence against general purpose LLMs, use of Dexcom's CGM in children, and more.
    STAT · 19d ago↗ source
  • HHS plan to speed drug research won’t remove ‘self-inflicted’ delays
    U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?
    BioPharma Dive · 19d ago↗ source
  • AstraZeneca, Ionis drug fails big heart disease study in major setback
    Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.
    BioPharma Dive · 19d ago↗ source
  • Who’s going to run the FDA?
    RFK Jr.'s list of Covid vaccine injuries, a father's quest to cure his daughter, and more health news from Morning Rounds
    STAT · 19d ago↗ source
  • STAT+: 931 days. The drug approval scandal hiding in plain sight
    Two years, six months, and 18 days have elapsed since Northwest Biotherapeutics submitted its brain cancer treatment for regulatory approval.
    STAT · 19d ago↗ source
  • STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
    AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
    STAT · 19d ago↗ source
  • Opinion: Your grandparents are using cannabis. Doctors can help them do it safely
    Over the past 25 years, I have treated thousands of medical cannabis patients with extremely few ill effects, one doctor writes.
    STAT · 19d ago↗ source